Skip to main content
SpringerLink
Log in

Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century

  • Review
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Polycythemia vera (PV) is a myeloproliferative tumor with low incidence and complex symptoms, affecting patients' quality of life and shortening their life span. Since the beginning of the 21st century, there has been an update but a need for uniform consensus regarding diagnosing and treating PV. With the continued interest of researchers in this field, a bibliometric study of PV is necessary. This paper aims to analyze articles on PV through bibliometric software to provide collaborative information and new ideas for researchers in this field. We collected PV-related publications in the Web of Science Core Collection database from 2000 to 2023. The included literature was analyzed using Citespace (6.2.R2), VOSviewer (1.6.19), and Bibliometrix. The study included country/region, institution, authors, journals, keywords, and references, and a visual knowledge network diagram was constructed. Microsoft Excel 2013 was also used for statistical analysis. A total of 1,093 articles were eventually included. The number of PV-related publications has steadily increased from 2000 to the present, with great potential for future growth. The US and US institutions have contributed more to this field, with the US ranking first in the number of publications, total citations, and centrality. Alessandro M. Vannucchi is the most published author. Tefferi, Ayalew is the most cited author. And BLOOD has the most publications, topping the list of the eleven high-productivity core source journals. The most cited article was "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders" (Baxter, EJ, 2005). By examining the keywords, we found that the diagnosis and typing of true erythrocytosis, the use of ruxolitinib, and the tyrosine kinase JAK2 are the research hotspots in the field; genetic and molecular research in the field of true erythrocytosis is a cutting-edge topic in the field; and risk factors for true erythrocytosis is a cutting-edge hotspot issue in the field. The fruitful research in this century has laid the foundation for developing the field of PV. The information in this article will provide researchers with current hotspots and future potential in the discipline, helping the field achieve more extraordinary breakthroughs. Currently, research should focus on increasing global multicenter collaborative research in diagnosis and treatment to develop scientifically recognized diagnostic and treatment protocols and new clinical drug research. Our proposed model of global innovation collaboration will provide strong support for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Abbreviations

PV:

Polycythemia vera

MPN:

Myeloproliferative neoplasm

MF:

Myelofibrosis

WOSCC:

Web of Science Core Collection

References

  1. Hermouet S (2023) Mutations, inflammation and phenotype of myeloproliferative neoplasms. Front Oncol 13. https://doi.org/10.3389/fonc.2023.1196817

  2. Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S (2023) Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 102:571–581. https://doi.org/10.1007/s00277-023-05089-6

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 98:1465–1487. https://doi.org/10.1002/ajh.27002

    Article  CAS  PubMed  Google Scholar 

  4. Tremblay D, Kosiorek HE, Dueck AC, Hoffman R (2021) Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia. Front Oncol 10. https://doi.org/10.3389/fonc.2020.636675

  5. Kuykendall AT (2023) Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. Ann Hematol. https://doi.org/10.1007/s00277-023-05172-y

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, Silver RT, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertu L, Arcaini L, Vannucchi AM, Passamonti F (2022) Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia 36:2453–2460. https://doi.org/10.1038/s41375-022-01673-3

    Article  CAS  PubMed  Google Scholar 

  7. Kokol P, Vosner HB, Zavrsnik J (2021) Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Info Libr J 38:125–138. https://doi.org/10.1111/hir.12295

    Article  PubMed  Google Scholar 

  8. Thompson DF, Walker CK (2015) A Descriptive and Historical Review of Bibliometrics with Applications to Medical Sciences. Pharmacotherapy 35:551–559. https://doi.org/10.1002/phar.1586

    Article  PubMed  Google Scholar 

  9. Liu WS (2021) Caveats for the use of Web of Science Core Collection in old literature retrieval and historical bibliometric analysis. Technol Forecast Soc Change 172. https://doi.org/10.1016/j.techfore.2021.121023

  10. Huang Y, Chen ZJ, Shen G, Fang SG, Zheng JJ, Chi ZP, Zhang YF, Zou YT, Gan QH, Liao CX, Yao YH, Kong JQ, Fan XX (2024) Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis. Hum Vaccines Immunotherapeutics 20. https://doi.org/10.1080/21645515.2024.2318815

  11. Yeung AWK (2019) Comparison between Scopus, Web of Science, PubMed and publishers for mislabelled review papers. Curr Sci 116:1909-+. https://doi.org/10.18520/cs/v116/i11/1909-1914

  12. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G (2008) Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. Faseb j 22:338–342. https://doi.org/10.1096/fj.07-9492LSF

    Article  CAS  PubMed  Google Scholar 

  13. Ninkov A, Frank JR, Maggio LA (2022) Bibliometrics: Methods for studying academic publishing. Perspect Med Educ 11:173–176. https://doi.org/10.1007/s40037-021-00695-4

    Article  PubMed  Google Scholar 

  14. van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523–538. https://doi.org/10.1007/s11192-009-0146-3

    Article  PubMed  Google Scholar 

  15. Aria M, Cuccurullo C (2017) bibliometrix: An R-tool for comprehensive science mapping analysis. J Informet 11:959–975. https://doi.org/10.1016/j.joi.2017.08.007

    Article  Google Scholar 

  16. Fernandez-Luna JL, Silva M, Richard C, Sanz C, Benito A (1998) Pathogenesis of polycythemia vera. Haematologica 83:150–158

    CAS  PubMed  Google Scholar 

  17. Bohiltea RE, Niculescu-Mizil E, Mihai BM, Furtunescu F, Ducu I, Munteanu O, Georgescu TA, Grigoriu C (2022) Polycythemia vera in pregnancy represents a challenge for a multidisciplinary collaboration: A case report and literature review. Exp Ther Med 23. https://doi.org/10.3892/etm.2021.10941

  18. Stoops K, Kuril S (2023) Ruxolitinib in a Child With JAK2 Exon 12 Mutant Polycythemia Vera. J Pediatr Hematol Oncol 45:E502–E505. https://doi.org/10.1097/mph.0000000000002549

    Article  CAS  PubMed  Google Scholar 

  19. Chornenki NLJ, Chai-Adisaksopha C, Leonh DP, Siegal DM, Hillis CM (2018) The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. Leuk Res 70:62–66. https://doi.org/10.1016/j.leukres.2018.06.001

    Article  Google Scholar 

  20. Aini W, Xie LM, Hu WY, Tang Y, Peng HL, Zhang GS, Deng T (2023) Exploration and identification of anoikis-related genes in polycythemia vera. Front Genet 14. https://doi.org/10.3389/fgene.2023.1139351

  21. Tefferi A, Barbui T (2017) Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92:95–108. https://doi.org/10.1002/ajh.24607

    Article  CAS  Google Scholar 

  22. Tefferi A, Barbui T (2019) Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 94:133–143. https://doi.org/10.1002/ajh.25303

    Article  PubMed  Google Scholar 

  23. Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95:1599–1613. https://doi.org/10.1002/ajh.26008

    Article  CAS  PubMed  Google Scholar 

  24. Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R (2019) Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 134:1498–1509. https://doi.org/10.1182/blood.2019000428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM (2014) A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea. Cancer 120:513–520. https://doi.org/10.1002/cncr.28441

    Article  CAS  PubMed  Google Scholar 

  26. Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A (2021) Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 8:e175–e184. https://doi.org/10.1016/s2352-3026(20)30373-2

    Article  CAS  PubMed  Google Scholar 

  27. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Kabat MG, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Calderon EB, Patriarca A, Cervantes KQ, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Mazo EM, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Serrano MS, Kusec R, Elorza BN, Angona A, Cirici BX, Abadia EL, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM (2022) Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. Am J Hematol 97:E470–E473. https://doi.org/10.1002/ajh.26732

    Article  CAS  PubMed  Google Scholar 

  28. Tefferi A, Vannucchi AM, Barbui T (2021) Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 35:3339–3351. https://doi.org/10.1038/s41375-021-01401-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tefferi A (2023) Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:801–821. https://doi.org/10.1002/ajh.26857

    Article  CAS  PubMed  Google Scholar 

  30. Baxter EJ, Scott LM, Campbell PJ (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (vol 365, pg 1054, 2005). Lancet 366:122–122

    Google Scholar 

  31. Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18:88–99. https://doi.org/10.1016/s1470-2045(16)30558-7

    Article  CAS  PubMed  Google Scholar 

  32. Barbuil T, Tefferi A, Vannucchi AM, Passamonti F, Silvers RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzil G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057–1069. https://doi.org/10.1038/s41375-018-0077-1

    Article  Google Scholar 

  33. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ, Grp P-PS (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7:E196-E208. https://doi.org/10.1016/s2352-3026(19)30236-4

  34. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen WN, Chen XY, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu SM, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao WB, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36:1703–1719. https://doi.org/10.1038/s41375-022-01613-1

  35. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper SS, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ, Comm BSH (2019) A guideline for the diagnosis and management of polycythaemia vera. A british society for haematology guideline. British J Haematol 184:176–191. https://doi.org/10.1111/bjh.15648

    Article  Google Scholar 

  36. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881. https://doi.org/10.1038/leu.2013.163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V (2023) Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. Cancers 15. https://doi.org/10.3390/cancers15143706

  38. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R (2015) Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:1762–1769. https://doi.org/10.1182/blood-2015-04-637280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H, Grp P-PS (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36:1408–1411. https://doi.org/10.1038/s41375-022-01528-x

  40. Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S (2015) Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol 8:391–401. https://doi.org/10.1586/17474086.2015.1045869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li JJ, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. N Engl J Med 372:426–435. https://doi.org/10.1056/NEJMoa1409002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ (2017) Ruxolitinib reduces JAK2 p. V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol 96:1113–1120. https://doi.org/10.1007/s00277-017-2994-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Moliterno AR, Kaizer H, Reeves BN (2023) <i>JAK2</i><SUP>V617F</SUP> allele burden in polycythemia vera: burden of proof. Blood 141:1934–1942. https://doi.org/10.1182/blood.2022017697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B (2011) The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 86:148–155. https://doi.org/10.1111/j.1600-0609.2010.01548.x

    Article  PubMed  Google Scholar 

  45. Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT (2014) Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28:935–938. https://doi.org/10.1038/leu.2014.7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kandarpa M, Robinson D, Wu YM, Qin T, Pettit K, Li Q, Luker G, Sartor M, Chinnaiyan A, Talpaz M (2024) Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations. Clin Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-23-0372

    Article  PubMed  Google Scholar 

  47. Elli EM, Mauri M, D'Aliberti D, Crespiatico I, Fontana D, Redaelli S, Pelucchi S, Spinelli S, Manghisi B, Cavalca F, Aroldi A, Ripamonti A, Ferrari S, Palamini S, Mottadelli F, Massimino L, Ramazzotti D, Cazzaniga G, Piperno A, Gambacorti-Passerini C, Piazza R (2024) Idiopathic erythrocytosis: a germline disease? Clin Exp Med 24. https://doi.org/10.1007/s10238-023-01283-y

Download references

Funding

This research was supported by Shandong Provincial TCM Science and Technology Development Program (grant no. 2019–0972).

Author information

Authors and Affiliations

  1. First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China

    Zhengjiu Cui & Yuan Zhang

  2. First College of Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing, China

    Fei Luo

  3. Department of Pediatrics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

    Juanjuan Diao & Yueli Pan

Authors
  1. Zhengjiu Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juanjuan Diao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yueli Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CZJ designed the study and drafted the manuscript. LF and DJJ searched strategy. CZJ, ZY and LF completed the statistical analysis. DJJ and PYL reviewed and modified the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Juanjuan Diao or Yueli Pan.

Ethics declarations

Declarations

No animal studies are presented in this manuscript.

No human studies are presented in this manuscript.

No potentially identifiable human images or data is presented in this study.

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 12 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, Z., Luo, F., Zhang, Y. et al. Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century. Ann Hematol (2024). https://doi.org/10.1007/s00277-024-05723-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00277-024-05723-x

Keywords

Search

Navigation